This document provides an agenda for the Cell Line Asia conference taking place on May 20-21, 2015 in Singapore. The conference will focus on strategies and technologies for developing robust cell lines at high quality and scale for biopharmaceutical production. The agenda lists over 30 speakers from companies in China, USA, and Singapore who will present on topics such as novel cell line development platforms, high-throughput analytical methods, media optimization, glycosylation analysis, bioprocess design and scale-up strategies, and next-generation bioprocessing trends. There will also be panel discussions, networking events, and two pre-conference workshops on design of experiments applications and bioprocess technology transfer. The conference is aimed at cell line developers

1. Part of
IBC
LIFE SCIENCES
Produced by:
www.celllineasia.com
Supporting
Association:
Media Partners:
Exhibitor:Associate Sponsor: Session Spotlight Sponsors:
International Marketing
Partner:
Pengfei Zhou
CEO,
Wuhan YZY Biopharma,
China
Accelerating Robust Cell Line Generation with High Quality
& Scalability in Production
2015 Expert Faculty Include: Key Strategies for Increasing
Productivity & Quality in your Cell Line
Development
Reduce Timelines in your Clone
Selection & Screening process
Scale-Up Strategies & Next-Generation
Bioprocessing Insights
Getting the Most out of Transient and
Stable Expression Systems
Omics Approaches to Enhance Cell
Culture Performance and Product
Quality
Optimising Glycosylation for Enhanced
Properties
Individual Optimization of Chemically
Defined Media
Critical Quality Attributes (CQA) &
Quality by Design (QbD)
Implementation Strategies
New Topics for 2015:
Xiang Yang Zhu
CEO,
Huaota Biopharm,
China
Scott Liu
CEO,
Henlius
Pharmaceuticals, USA
Pei Ye
Vice President,
Beijing Mabworks
Biotech, China
Zhiwei Pan
Senior Director,
Cell Culture Process
Development,
Livzon mAbpharm,
China
Pre-Conference Workshops Not to be Missed | 19 May 2015
Best Practices in Process Technology Transfer
and cGMP Manufacturing
Achieving Operational Excellence in
Bioprocessing: Design of Experiments (DoE)
Applications for Cell Culture
A
B
PLUS! An Exclusive
Post-Conference
Special Focus Day | 22 May 2015
Cutting Edge Trends in
Antibody Development
Peng Wang
President of R&D,
Yabao
Pharmaceutical
Group, China
Life
Sciences

2. REGISTER TODAY! +65 6508 2401 register@ibcasia.com.sg www.celllineasia.com
CONFERENCE DAY ONE
20 May 2015 | Wednesday
12:40 Integrating Multi-Omics Analysis & In Silico Modelling of
CHO Cells for Enhancing Cell Culture Performance and
Product Quality
• Mammalian systems biotechnology framework
• Integrated bioinformatics platform for multi-omics profiling and
analysis
• Genome-scale metabolic/regulatory modelling and in silico
analysis of CHO cells
• Characterizing cell cultures and identifying metabolic and
regulatory signatures for cell line development
Dong-Yup Lee, Assistant Professor, Department of Chemical
and Biomolecular Engineering, NUS, Singapore
1:10 Networking Luncheon & VIP Tables
VIP Table 1: Peng Wang, President of R&D,
Yabao Pharmaceutical Group, China______________________________________________________________________________________________
VIP Table 2: Zou Ping, Vice Director,
Shanghai CPGJ Pharma, China______________________________________________________________________________________________
VIP Table 3: John Xu, CSO, Shanghai Benemae Pharma &
VP, Shanghai Mabicine, China______________________________________________________________________________________________
Exchange business cards and have an informal chat with the
above guests during the networking lunch!
2:30 Roundtable Discussions
Each leader will facilitate the discussion for 45 minutes. Leaders will
then share key takeaways on the stage for 5 minutes each. Choose your
table now! Email sonia.jaya@ibcasia.com.sg______________________________________________________________________________________________
Novel Cell Line Development and Bioprocess Approaches
for Increased Speed, Titer and Product Quality
Cheng Zhang, CSO, Gmax Biopharm, China______________________________________________________________________________________________
Strategies on Raw Material and Supplier Management
for Efficient, Cost-effective Biopharmaceutical Production
Chiali Liu, Manager, Microbial and Cell Culture Development,
GSK, USA______________________________________________________________________________________________
Applying Essential QbD Strategies in Cell Culture and
Bioprocess Deveopment for Biopharmaceuticals
Hung Fai Poon, Director,CellCulture, Hisun Pharmaceuticals,
China
3:30 Afternoon Networking & Refreshment Break
Cell Culture Media for Optimized Growth
4: 10 Individual Optimization of Chemically Defined Media
• Best practices in media formulation, optimization and preparation
• Implementing the most optimal conditions
• How can the host cell be made to effectively preadapt to
suspension and serum-free media, and thus cutting short the
overall developmental timeline?
• Optimizing medium for a fed batch culture or develop an
optimized growth medium for large scale production
• Analytical tools and high-throughput protocols in increasing cell
densities
Chuan He, Process Development, Senior Scientist,
Beijing Mabworks Biotech, China
Optimising Glycosylation
4:50 High Throughput & High Resolution Glycosylation
Analysis Throughout Bioprocess Development for
Improved Quality
• How does the glycosylation profile impact quality of bioproducts
• How glycosylation variation can affect structure, effector function
and product stability
• Importance of glycosylation analysis in bioprocess development
• Strategies and techniques to incorporate glycosylation analysis
in bioprocessing for high quality products
DrPeiqingZhang, AssistantProfessor,DepartmentofAnatomy,
Yong Loo Lin School of Medicine, NUS Singapore
5:30 Chairperson’s Closing Remarks &
End of Conference Day One
6:00 Networking Cocktail
VIP 1: Scott Liu, CEO, Henlius Pharmaceuticals, USA______________________________________________________________________________________________
VIP 2: Feng Tian, Head and Director, Ambrx China______________________________________________________________________________________________
VIP3 : Wen-Chen Suen, Chief Scientific Officer, Biologics
Division, HEC Pharm, China
Exchange business cards and visit the above guests!
KEYNOTEPANELCEOPANEL
08:00 Registration Opens & Morning Coffee
08:50 Welcome Address from IBC Asia & Speed Networking
09:00 Chairperson’s Opening Remarks
Abdullah Baaj, CEO, Boston Oncology, USA
Biopharma Visionary Keynote Sessions
9:05 Global Biopharma Outlook: Opportunities & Challenges
2015 & Beyond
• Macro-analysis of the current biopharma environment and market
drivers
• What are the constraints, opportunities and challenges?
• Innovation in the industry – who is taking the lead? Who are the
silent players?
• How is Big Pharma and Biologics Majors reacting to the Biosimilars
opportunity?
• Where are the Next Generation MaBs Biosimilars likely to come
from?
• Is there money to be made from Biosimilars?
• Pros and cons of serving multiple growing markets
Moderator: Yariv Hefez, Vice President Business Development,
Portfolio Management, Strategy and Partnering, Biosimilars
Unit, Merck Serono, Switzerland
Panelists:
Abdullah Baaj, CEO, Boston Oncology, USA
Racho Jordanov, President & CEO, JHL Biotech, Taiwan
Richard O’Keeffe, Executive Director, International Quality –
Japan-Asia-Pacific (JAPAC) Regional Quality Head, Amgen,
Singapore
9.45 Cutting Edge Insights into China’s Growing Biotech
Market
• Perspectives on China’s biotech policies, regulation and markets
• Can Chinese Biosmilar brands compete effectively against Indian
and Korean Biosimilars globally?
• Information on the local regulatory and Government policies
• Private vs publicly funded biopharma research and development
• Growth strategies and key for success in a highly competitive
market
Moderator: Shou-Bai Chao, SeniorVicePresident,BioVentures,
Global Operations, AstraZeneca, China
Panelists:
Joe Zhou, CEO, Walvax Group, China
Li Shi, CEO, Shanghai Zerun Biotechnology, China
Michelle Yu Xia, Chairman, President & CEO,
Akeso Biopharma, China
Scott Liu, CEO, Henlius Pharmaceuticals, USA
10.25 China’s Evolving Biopharma Policies & Regulations
• Update on China’s Biosimilars guidelines and biologic regulations
• Biomanufacturing standards
• Testing, GMP Inspections and product quality
SeniorRepresentative, China Food and Drug Administration
(CFDA), China
10:50 Morning Networking and Refreshment Break
Advances in Clone Screening and Selection
11: 30 Chairperson’s Opening Remarks
Pengfei Zhou, CEO, Wuhan YZY Biopharma Co Ltd, China
11:40 Efficient Screening Strategies to Select Clones & Reduce
Timelines
• Current challenges in streamlining selection and clonal isolation
• Review of latest technologies to overcome these challenges and
suggestions to reduce timelines
• Combining image processing and document tracking system for
effective clone- picking
• Clonal cell lines selection using Cell MetricTM CLD
Chaomei He, PrincipalScientist, Momenta Pharmaceuticals,
USA
Analytical Strategies for Increased
Quality in Bioproduction
12:10 High-Throughput (HTP) Analytical Platforms to Assess
Product Quality Attributes in Cell Lines
• What are the major challenges met when using these HTP
technologies, especially in mammalian cell line development?
• Novel HT technologies available for increased productivity and
quality
• HTP analytical assays to facilitate product quality in the early
stage of clone screening to hasten process development
Senior Representative, Lonza
GOVERNMENT
ADDRESS

3. REGISTER TODAY! +65 6508 2401 register@ibcasia.com.sg www.celllineasia.com
CONFERENCE DAY TWO
21 May 2015 | Thursday
9:00 Chairperson’s Opening Remarks
HungFaiPoon, Director,CellCulture, HisunPharmaceuticals,
China
Novel Cell line Development Platforms &
Expression Systems
9:05 Cell Line Development Platforms: AnalyzingVarious Cell
Line Expression Platforms
• Review of mammalian vs non-mammalian expression systems
• Comparison of safety, cost and quality of various cell lines
• Future trends in moving away from CHO cell lines
• Novel expression systems – Case study of Amgen’s targeted
integration approach
Dayou Liu, Senior Scientist, Amgen, USA
9:40 Getting the Most Out of Stable and Transient
Expression Systems
• Review and discussion of stable vs transient cell lines- pros and
cons
• Overcoming the regulatory hurdles involved
• Recent advances in transient transfection and cell culture methods
• Suspension cell culture lines vs in plated cell lines
Panelists:
Xiang Yang Zhu, CEO, Huaota Biopharm, China
Dayou Liu, Senior Scientist, Amgen, USA
Cheng Zhang CSO, Gmax Biopharm, China
10:20 Morning Networking and Refreshment Break
10:50 Using Targeted Genome Engineering to Advance CHO
Cell Technology
• Horizon’s GS Null cells
~ Industry need
~ Engineering
• Critical Quality Attributes (CQAs) in cell production systems:
what makes a “Good CHO”?
• Using engineering to improve these CQAs
~ Different engineering technologies
~ Different targets
~ Large scale engineering in one line
• Future plans to continue revolutionizing Cell line development
in Bioproduction
Dr Jamie Freeman, Bioproduction Product Manager,
Horizon Discovery, U.K
11:30 Overcoming the ‘Position Effect’– Targeting Integration
into Chromosomal Hotspots for Rapid Cell Line
Development
• Strategies for identification of chromosomal integration sites
which provide high and stable gene expression
• Enhancing efficiency of targeted integration using cutting-edge
technologies (Meganuclease, ZFN, TALEN and CRISP)
• Different vector designs for co-expression of light chain and
heavy chain and impact on monoclonal antibody expression and
quality
Yuan Sheng Yang, Senior Staff Research Scientist,
Bioprocessing Technology Institute, Singapore
Efficient Bioprocess Design & Scale-up
Strategies
12:10 Bioprocess Design Strategies to Increase Quality
and Efficiency
• Developing a QbD strategy in cell line and process development
• Considerations for the quality and safety of materials in contact
with biologics
• Tips to accelerate biopharmaceutical development
~ Define and align development activities for each stage
~ Streamlining technlogy transfer processes
~ Applying single-use technologies
Zhiwei Pan, Senior Director, Cell Culture Process Development,
Livzon mAbpharm, China
12:50 Networking Luncheon
______________________________________________________________________________________________
VIP Table 1: Pengfei Zhou, CEO, Wuhan YZY Biopharma
Co Ltd, China
______________________________________________________________________________________________
VIP Table 2: Andy Tsun, Senior Manager & Group Head,
Novel Drug and Cell Line Development,
Innovent Biologics, China
______________________________________________________________________________________________
VIP Table 3: XiangYang Zhu, CEO, Huaota Biopharm, China
______________________________________________________________________________________________
Exchange business cards and have an informal chat with the
above guests during the networking lunch!
2:30 Feeding and Bioreactor Strategies for Efficient Scale up
• Which cell culture process to choose – Fed-batch vs continuous-
perfusion culture review
• Case Study on Single-use disposable / miniature bioreactors for
clone selection
• High-titre cell culture processes and scale up strategies
Hao Chen, Principal Scientist, Merck, USA
3:10 Ensuring Success in Scaling up the Cell Culture Process
• Strategies to maximize productivity, enhance process
reproducibility and facilitate scale-up
• Being aware of scale-up effects on process performance and
product quality
• Questions and considerations when moving to production scale
• Tools and studies to help answer the questions
• Developing a strategy for efficient scale-up
Chiali Liu, Manager, Microbial and Cell Culture Development,
GSK, USA
3:50 Afternoon Networking and Refreshment Break
Next-Generation Bioprocessing Trends
4:20 Insights into Next-Generation Bioprocessing
• Future of bioprocessing and trends
• Determining your key objectives: predictability, consistency,
increased titers and higher quality
• Novel process controls, biosensor tools to increase efficiency of
bioprocessing
• Smooth integration and linking of upstream and downstream
processes
• Incorporating systems biology techniques
• Latest technologies and tools in bioprocessing to accelerate
biopharmaceutical development
Moderator: Prof Rolf G Werner, Industrial Biotechnology
Department, University of Tubingen, Germany
Panelists:
Chiali Liu, Manager, Microbial and Cell Culture Development,
GSK, USA
Hao Chen, Principal Scientist, Merck, USA
Zhiwei Pan, Senior Director, Cell Culture Process Development,
Livzon mAbpharm, China
5:00 Chairperson’s Closing Remarks &
End of Conference Day Two
PANELDISCUSSION
PANELDISCUSSION

4. REGISTER TODAY! +65 6508 2401 register@ibcasia.com.sg www.celllineasia.com
WO R KS H O P S
DoE is central to the Quality by Design (QbD) concept because it
defines the design space of cell culture media and bioprocesses.
Therefore, this workshop will focus on the application of DoE methods
via the use of statistical software, bioprocess case studies, and hands-
on software exercise and its application to multivariate analysis (MVA)
during the optimization of culture media and bioprocesses.The case
studies will focus on CHO cell culture with data to investigate the
effects of factors such as medium components, pH, and temperature
etc on cell culture productivity and protein critical quality attributes
(CQA).
• Basic statistical concepts required for DoE
• How to design and analyze experiments for media and process
optimization using mixture, factorial, fractional factorial, and
response surface design
• How to interpret the output of experimental design software
• How to use the popular DoE software in designing and using MVA
software to analyze experiments
About Your Workshop Leader:
Dr Hung Fai Poon, R&DDirector,CellCulture, Hisun Pharmaceuticals,
China
Dr. Poon is currently the director of Cell Culture in Hisun Pharmaceuticals. He
previously worked for SAFC, Roskamp Institute in USA. He completed his
Ph.D. in Biological Chemistry at University of Kentucky, and MBA from
University of South Florida. He has years of experience in the field of biological,
analytical research, bioinformatics and proteomics. He has more than 10 years
of cell culture experience with focus on biopharmaceutical products.
He has published more than 30 peer-reviewed articles, and contributes to
more than 5 book chapters. He is currently the associate Editor for Journal
of Chemistry, Biochemistry and Molecular Biology, and Journal of
Bioinformatics and Biometrics.
PRE-CONFERENCE WORKSHOP
19 MAY 2015: 9.00am - 12:30 pm
A
PRE-CONFERENCE WORKSHOP
19 MAY 2015: 1.30pm - 5:00 pm
B
The workshop will cover the key aspects of bioprocess technology
transfer for cGMP manufacturing. It will be a short practical course
focusing on smooth scale-up, well-prepared technical transfer, and
examine how new trends and developments in bioprocessing
technology is best developed and translated to a GMP-robust
manufacturing environment.
• Process development and optimization
• Project management and communication
• Raw material and supply chain management
• Confirmation batches and process fit analysis
• Document review and approval
• Deviation and investigation
• Case Studies
About Your Workshop Leader:
Hao Chen, Principal Scientist, Merck USA
Dr. Hao Chen is a Principal Scientist in BioProcess Development at Merck
Research Laboratories (Kenilworth, NJ, USA). He currently leads the Upstream
& Recovery Process Development group for process development, scale-up,
tech transfer, and initial process characterization. His group supports cell
culture and fermentation projects from preclinical to commercial stage,
including regulatory filings. Prior to Merck, he worked on upstream
process/medium development and tech transfer for cell culture and
fermentation in various companies including Becton Dickinson (BD) and
Amylin Pharmaceuticals.
Dr. Chen received his Ph.D. degree in Chemical Engineering from Purdue
University. He also holds an MS in Biochemical Engineering and a BS in Fine
Chemical Engineering, from Zhejiang University.
POST-CONFERENCE WORKSHOP
SPECIAL FOCUS DAY
22 May 2015
Best Practices in Process Technology
Transfer and cGMP Manufacturing
Achieving Operational Excellence in
Bioprocessing: Design of Experiments
(DoE) Applications for Cell Culture
Cutting Edge Trends in
Antibody Development
9:00 Chairperson’s Opening Remarks
Weidong Jian, CSO & VP, Henlius Biopharmaceuticals, USA
9:10 Strategies for Novel Antibodies and Biosimilars
Development
• Selecting the right and appropriate clones for novel antibodies
and biosimilars
• Developing a high expression, cost-effective cell line for antibodies
• Case studies on Biosimilars development -Maintaining quality
and quantity in biosimilars cell line development
Pei Ye, Vice President, Beijing Mabworks Biotech, China
9:50 Novel Methods in Antibody Discovery and
Characterization
• Screening for the Optimal Antibody Development Candidate
Outline Profile (DCOP)
• Strategies in antibody characterization to ascertain the
identification of antibody drug candidates
• ADCs, bispecifics analytic strategies and characterization
• Case study: Biobetters and bispecific mAb initiatives
Weidong Jian, CSO & VP, Henlius Biopharmaceuticals, USA
10:30 Morning Networking and Refreshment Break
11:00 StrategiesinCellLineEngineeringofBiSpecificAntibodies
• Challenges involving finding bispecific target pairs
• Optimising the antigen expression patterns
• Identifying the target criteria for different format types
Pengfei Zhou, CEO, Wuhan YZY Biopharma Co Ltd, China
11:40 Boosting Productivity and Efficiency of Biotherapeutics
• Achieve high titers via expression vector and secretory pathways
• Using efficient resins and sequential chromatography to attain
high yields
• Attaining product efficacy and long serum half life for low doses
• High concentration liquid formulation techniques and convenient
application processes
Prof Rolf G Werner, Industrial Biotechnology Department,
University of Tubingen, Germany
12:20 Networking Lunch
1:30 Novel Strategies in Monoclonal Antibodies Targeting
GPCRs
• Difficulties in generating functional antibodies against GPCRs
and possible methods to overcome this
• An integrated Mab platform to generate functional Mabs against
GPCRs
• Development of the Mabs towards biotherapeutics
Cheng Zhang, CSO, Gmax Biopharm
2:10 Strategies in Fc Effector Function Analysis in Antibodies
• Assessing effector functions
• Ensuring similarity to original compound
• Strategies and integrated multi-assay approaches
Jingyi Xiang, Head of Bioanalytics, Eureka Pharma, USA
2:50 Afternoon Refreshements
3:20 Engineering of Antibody Drug Conjugates (ADCs)
Technologies
• Established ADC technologies including monoclonal antibody
formats, linkers and payloads
• Analyzing ADC performance- in vitro potency versus in vivo
efficacy, and safety considerations
• ADC process development and scale up CMC strategies
• Strategies to enhance ADCC activity in ADCs
4:00 Chairperson’s Closing Remarks &
End of Post-Conference Special Focus Day
C

5. Part of
IBC
LIFE SCIENCES
Geography
■ China 50%
■ Japan, Korea, HK, Taiwan 15%
■ US 10%
■ Europe 10%
■ Southeast Asia 10%
■ Rest of world 5%
REGISTER TODAY! +65 6508 2401 register@ibcasia.com.sg www.celllineasia.com
“Over the years, the demand for
cell line development equipment,
media and reagents is likely to
increase owing to the increasing
demand for monoclonal antibodies,
rising vaccine production, and use
of innovative technologies to
develop cell lines. This market is
expected to reach $3.96 billion by
2019. However, in spite of innovative
technologies in the market,
developing stable and authentic cell
lines still remains a challenge.”
Markets and Markets,September 2014
IBC Asia’s 4th Annual Cell Line Development and Engineering Conference, provides
a platform for industry leaders from pharma/biotech, research institutes and technology
providers to discuss the challenges, trends and collaboration opportunities in conducting
cell line development in Asia.
An Under-One-Roof Approach!
In 2015, Cell Line Development & Engineering Asia will highlight exciting developments
in cell line engineering, explore efficient best practices in scaling up and bioprocessing
techniques, as well as delve into cutting edge techniques in antibody development,
all under-one-roof!
Develop robust cell lines with maximum quality, productivity and efficiency for scalability
in production. Glean effective bioprocessing and scale-up techniques, and also gain
the latest updates in antibody development with bispecifics, ADCs, and boosting
therapeutic efficiencies.
Update yourself with latest technologies to accelerate every stage of cell line development with
maximum efficiency, quality and reduced cost
Enhance cell line development in the early stages with best practices in transfection, optimizing
cell culture media, and implement advancements in clone screening and selection techniques
Gain effective bioprocess control and optimization strategies, for efficient, safe and cost
effective scale-up
Latest cutting edge updates on antibody development- novel screening strategies for
target discovery, challenges in ADCs, engineering bispecifics and boosting efficacy in
antibody therapeutics
Why You Should
Sponsor:
Position your company as a market leader
at this event and our customized
Sponsorship & Exhibition package offers
prime exposure to key decision-makers and
exceptional branding. To explore the range
of thought leadership, speaking, branding
and marketing opportunities available,
please contact Yvonne Leong
Tel: +65-6508-2489
Email: yvonne.leong@ibcasia.com.sg
WHY YOU MUST ATTEND THIS 2015
Who You Will Meet:
Industry Breakdown
■ Pharma/Biotech 55%
■ Research Institutes/Universities 15%
■ CMOs 5%
■ Technology Solution providers 20%
■ CROs 5%
About the BDP Week
The Biopharma Development & Production Week is the leading
industry platform for pharma, biotech, CMOs, CROs, research
institutes, investors, technology and industry stakeholders to meet,
network and discuss current industry trends, establish business
partnerships and be updated on investment opportunities in
China and surrounding Asia.
BIOBIO3 Conferences
in 1 Location

6. This label contains your priority booking code. To expedite registration, please do not remove label. If you have
already received a copy of this brochure, we apologise. For reasons of confidentiality, your full particulars were not
available to IBC Asia (S) Pte Ltd for deduplication prior to mail drop.
If undelivered, please return to:
111 Somerset Road,
TripleOne Somerset #10-06, Singapore 238164
Tel: +65 6508 2400 Fax: +65 6508 2408
4TH ANNUAL CELL LINE DEVELOPMENT & ENGINEERING ASIA
Email
register@ibcasia.com.sg
Fax
+65 6508 2407
Scan the QR Code with your
smartphone and register today
Customer Service Hotline
+65 6508 2401
MAIL the attached registration
form with your cheque to
IBC Asia (S) Pte Ltd
c/o Informa Regional Business
Services
111 Somerset Road,
TripleOne Somerset #10-06,
Singapore 238164
Web
www.celllineasia.com
HOTEL INFORMATION
DATA PROTECTION
PAYMENT TERMS
CANCELLATIONS / SUBSTITUTION
IMPORTANT NOTE
REGNO.200108203N
Payment must be received 10 business days prior to the event.
To take advantage of discounts with an expiry date, registration
and payment must be received by the cut-off date.
• Payment by bankers draft or cheque in S$ or US$ should be
made in favour of “IBC Asia (S) Pte Ltd” and mailed to:
IBC Asia (S) Pte Ltd
c/o Informa Regional Business Services
111 Somerset Road, TripleOne Somerset #10-06
Singapore 238164
Attn: The Accounts Receivable Team
• Payment by bank transfer in S$ or US$ made payable to:
IBC Asia (S) Pte Ltd
A/C No.:147-059513-001 (S$)
A/C No.:260-457866-178 (US$)
The Hongkong and Shanghai Banking Corporation Limited
21 Collyer Quay, HSBC Building
Singapore 049320
Bank Swift Code: HSBCSGSG
Bank Code: 7232
• Payment by Credit Card (AMEX, VISA or MasterCard).
The best way to pay by credit card is through our secure
portal built into the website. To pay by phone please indicate
the contact name and details below and our Customer
Services Team will call within 24 hours to take payment.
Please do not send credit card information by email.
The personal information entered during your registration/order,
or provided by you, will be held on a database and may be
shared with companies in the Informa Group in the UK and
internationally. Occasionally, your details may be obtained from
or shared with external companies who wish to communicate
with you offers related to your business activities. If you do not
wish your details to be used for this purpose, please contact
our Database Department at Email: database@ibcasia.com.sg,
Tel: +65 6508 2400 or Fax: +65 6508 2408.
Should you be unable to attend, a substitute delegate is
welcome at no extra charge. Cancellations must be received in
writing at least 10 business days before the start of the event,
to receive a refund less 10% processing fee per registration.
The company regrets that no refund will be made available for
cancellation notifications received less than 10 business days
before the event.
Please quote the name of the delegate, event title and invoice
number on the advice when remitting payment. Bank charges
are to be deducted from participating organisations own accounts.
Please fax your payment details (copy of remittance advice,
cheque or draft to +65 6508 2407).
Attendance will only be permitted upon receipt of full payment.
Participants wishing to register at the door are responsible to
ensure all details are as published. IBC assumes no further
liability or obligation, beyond the refund of the paid registration
fee, in the event of postponement or cancellation by IBC.
6 EASY WAYS TO REGISTER
RESERVE YOUR PLACE TODAY!
■ Yes! I/We will attend the 4th Cell Line Development & Engineering Asia
19 – 22 May 2015, Grand Hyatt Shanghai, China
■ I would like to purchase the conference presentations at SGD1000 + GST (SGD1070) per log in.
CREDIT CARD PAYMENTS
The best way to pay by credit card is through our secure on-line registration process, simply log on to the website at
www.celllineasia.com and click “Register On-line”. If you would prefer to pay over the phone please complete the contact name and
details and our Customer Services Team will call within 24 hours to take payment. As we treat your credit card information in the strictest
confidence, please do not send payment details by email.
Credit card contact: Department:
Direct phone number: Email:
P46262
Who is Head of your Department?
Who is Head of Training?
Company Information
Company Name:
Address:
Main Business/Activity:
Postal Code:
■ I enclose my bankers draft / cheque payable to IBC Asia (S) Pte Ltd
■ I am paying by bank transfer (copy attached)
■ Payment by Credit Card. (AMEX, VISA or MasterCard accepted)
PAYMENT METHOD
(Please tick)
Please photocopy for additional delegates
REGISTER TODAY! +65 6508 2401 register@ibcasia.com.sg www.celllineasia.com
• Multiple Bookings Discount pricing is applicable to groups of 3 or more delegates from the same organisation registering for the same event, at the same time.
Fee stated is the discounted price PER DELEGATE. Only one discount applies; either the early bird rate OR special rate OR group rate.
• All fees stated include luncheons, refreshments and complete set of documentation. It does not include the cost of accommodation and travel.
• Registration fees are subject to the prevailing government tax.
Early Bird Rate
Register & pay on or
before 13 Mar 2014
Special Rate
Register & pay on or
before 10 Apr 2015
Group Rate
(3 or more delegates)
Normal Rate
Register & pay after
10 Apr 2015
❑ 2 Day Conference only
FEE PER DELEGATE
❑ 4 Day Package: 2 Day Conference +
All Workshops
USD 2,795 USD 2,995 USD 3,195 USD 2,595
❑ 3.5 Day Package: 2 Day Conference +
Workshop C + A or B
Delegate 1 Details
Name: Dr/Mr/Ms
Job Title:
Department
Tel:
Mobile No.:
Email:
Delegate 2 Details
Name: Dr/Mr/Ms
Job Title:
Department
Tel:
Mobile No.:
Email:
❑ 3 Day Package: 2 Day Conference +
Workshop A + B or C
❑ 2.5 Day Package: 2 Day Conference +
Workshop A or B
USD 2,595 USD 2,795 USD 2,995 USD 2,395
USD 2,395 USD 2,595 USD 2,795 USD 2,195
USD 2,095 USD 2,295 USD 2,495 USD 1,895
USD 1,795 USD 1,995 USD 2,195 USD 1,595
❑ 2 Day Conference only
❑ 4 Day Package: 2 Day Conference +
All Workshops
CNY 7,500 CNY 8,500 CNY 9,000 CNY 7,000
CNY 7,000 CNY 8,000 CNY 8,500 CNY 6,500
CNY 6,500 CNY 7,500 CNY 8,000 CNY 6,000
CNY 6,000 CNY 7,000 CNY 7,500 CNY 5,500
CNY 5,500 CNY 6,500 CNY 7,000 CNY 5,000
Grand Hyatt Shanghai, China
Jin Mao Tower, 88 Century Boulevard
Pudong, Shanghai 200121
Tel: +86 21 5049 1234 | Fax: +86 21 5049 8381
Contact Person: Judy Xu
Email: judy.xu@hyatt.com
Domestic China Companies (Global Headquaters Located within Mainland China)
International Companies (Global Headquaters Located Outside of Mainland China)
Register 3 Delegates and
The 4th Attends For Free!
❑ 3.5 Day Package: 2 Day Conference +
Workshop C + A or B
❑ 3 Day Package: 2 Day Conference +
Workshop A + B or C
❑ 2.5 Day Package: 2 Day Conference +
Workshop A or B